Our experiments with a patient-derived cell model suggest that TGF-β signaling is required to induce the high-motility phenotype in tumor-derived reactive glia, whereas other pro-inflammatory cytokines like TNF-α may potentiate this phenotype by crosstalk with the NFκB pathway. The gene discussed is NFKB1; the disease is neoplasm.